{
    "code": "52026968",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026968",
    "time": "2021-06-18 04:45:43",
    "許可證字號": "衛部藥輸字第026968號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "110\/11\/10",
    "發證日期": "105\/11\/10",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202696807",
    "中文品名": "泰格莎膜衣錠80毫克",
    "英文品名": "TAGRISSO Film-coated Tablets 80 mg",
    "適應症": "1. EGFR突變陽性的非小細胞肺癌 (NSCLC) 之輔助治療：\r\n適用於腫瘤帶有表皮生長因子受體 (EGFR) 外顯子19缺失或外顯子21 L858R突變之非小細胞肺癌 (NSCLC) 病人，作為腫瘤切除後的輔助治療。\r\n2. EGFR突變陽性的轉移性NSCLC之第一線治療：\r\n適用於腫瘤具表皮生長因子受體 (EGFR) 突變之局部侵犯性或轉移性NSCLC病人的第一線治療。\r\n3. 曾接受治療之EGFR T790M突變陽性的轉移性NSCLC：\r\n適用於治療具有EGFR T790M基因突變之局部侵犯性或轉移性NSCLC在EGFR TKI治療期間或之後疾病惡化的病人。",
    "劑型": "116膜衣錠",
    "包裝": "2-1000錠鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "110\/11\/10",
    "主成分略述": "Osimertinib mesylate",
    "限制項目": "02輸　入 1S須執行確認性療效臨床試驗 5F免除銜接性試驗",
    "申請商名稱": "1434901100  臺灣阿斯特捷利康股份有限公司",
    "申請商地址": "台北市大安區敦化南路二段207號21樓",
    "主製造廠": [
        {
            "製造廠名稱": "FSE0032000  ASTRAZENECA AB",
            "製造廠廠址": "SE-151 85 SODERTALJE SWEDEN",
            "製造廠公司地址": "",
            "製造廠國別": "SWEDEN",
            "製程": ""
        }
    ],
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200082310",
            "成分名稱": "Osimertinib mesylate",
            "含量描述": "(1.192mg of osimertinib mesylate is equivalent to 1 mg of osimertinib freebase)",
            "含量": "95.4000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "TAGRISSO ZH-TW ADAUDA PI aligned with USPI 202012 clean-110-04-06.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026968&Seq=008&Type=9"
        },
        {
            "title": "TAGRISSO 80mg-鋁箔-PS07691-108-05-07(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026968&Seq=010&Type=8"
        },
        {
            "title": "TAGRISSO 80mg-NPS-鋁箔-PS09690-108-05-07(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026968&Seq=009&Type=8"
        },
        {
            "title": "TAGRISSO 80mg-NPS-外盒-PS09691-108-05-07(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026968&Seq=008&Type=8"
        },
        {
            "title": "TAGRISSO 80mg-10x3-外盒-PS14503-108-05-07(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026968&Seq=007&Type=8"
        },
        {
            "title": "TAGRISSO 80mg-10x1-外盒-PS07692-108-05-07(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026968&Seq=006&Type=8"
        },
        {
            "title": "TAGRISSO 80mg-鋁箔-PS07691-108-04-19(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026968&Seq=005&Type=8"
        },
        {
            "title": "TAGRISSO 80mg-10x3-外盒-PS14503-108-04-19(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026968&Seq=004&Type=8"
        },
        {
            "title": "TAGRISSO 80mg-10x1-外盒-PS07692-108-04-19(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026968&Seq=003&Type=8"
        },
        {
            "title": "026968-TAGRISSO 80mg-鋁箔-105-11-24.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026968&Seq=002&Type=8"
        }
    ]
}